Xvivo Perfusion AB
STO:XVIVO

Watchlist Manager
Xvivo Perfusion AB Logo
Xvivo Perfusion AB
STO:XVIVO
Watchlist
Price: 451.5 SEK 1.23% Market Closed
Market Cap: 14.2B SEK
Have any thoughts about
Xvivo Perfusion AB?
Write Note

Intrinsic Value

The intrinsic value of one XVIVO stock under the Base Case scenario is 251.13 SEK. Compared to the current market price of 451.5 SEK, Xvivo Perfusion AB is Overvalued by 44%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

XVIVO Intrinsic Value
251.13 SEK
Overvaluation 44%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Xvivo Perfusion AB

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for XVIVO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about XVIVO?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Xvivo Perfusion AB

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Xvivo Perfusion AB

Provide an overview of the primary business activities
of Xvivo Perfusion AB.

What unique competitive advantages
does Xvivo Perfusion AB hold over its rivals?

What risks and challenges
does Xvivo Perfusion AB face in the near future?

Has there been any significant insider trading activity
in Xvivo Perfusion AB recently?

Summarize the latest earnings call
of Xvivo Perfusion AB.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Xvivo Perfusion AB.

Provide P/S
for Xvivo Perfusion AB.

Provide P/E
for Xvivo Perfusion AB.

Provide P/OCF
for Xvivo Perfusion AB.

Provide P/FCFE
for Xvivo Perfusion AB.

Provide P/B
for Xvivo Perfusion AB.

Provide EV/S
for Xvivo Perfusion AB.

Provide EV/GP
for Xvivo Perfusion AB.

Provide EV/EBITDA
for Xvivo Perfusion AB.

Provide EV/EBIT
for Xvivo Perfusion AB.

Provide EV/OCF
for Xvivo Perfusion AB.

Provide EV/FCFF
for Xvivo Perfusion AB.

Provide EV/IC
for Xvivo Perfusion AB.

Show me price targets
for Xvivo Perfusion AB made by professional analysts.

What are the Revenue projections
for Xvivo Perfusion AB?

How accurate were the past Revenue estimates
for Xvivo Perfusion AB?

What are the Net Income projections
for Xvivo Perfusion AB?

How accurate were the past Net Income estimates
for Xvivo Perfusion AB?

What are the EPS projections
for Xvivo Perfusion AB?

How accurate were the past EPS estimates
for Xvivo Perfusion AB?

What are the EBIT projections
for Xvivo Perfusion AB?

How accurate were the past EBIT estimates
for Xvivo Perfusion AB?

Compare the revenue forecasts
for Xvivo Perfusion AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Xvivo Perfusion AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Xvivo Perfusion AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of Xvivo Perfusion AB compared to its peers.

Compare the P/E ratios
of Xvivo Perfusion AB against its peers.

Discuss the investment returns and shareholder value creation
comparing Xvivo Perfusion AB with its peers.

Analyze the financial leverage
of Xvivo Perfusion AB compared to its main competitors.

Show all profitability ratios
for Xvivo Perfusion AB.

Provide ROE
for Xvivo Perfusion AB.

Provide ROA
for Xvivo Perfusion AB.

Provide ROIC
for Xvivo Perfusion AB.

Provide ROCE
for Xvivo Perfusion AB.

Provide Gross Margin
for Xvivo Perfusion AB.

Provide Operating Margin
for Xvivo Perfusion AB.

Provide Net Margin
for Xvivo Perfusion AB.

Provide FCF Margin
for Xvivo Perfusion AB.

Show all solvency ratios
for Xvivo Perfusion AB.

Provide D/E Ratio
for Xvivo Perfusion AB.

Provide D/A Ratio
for Xvivo Perfusion AB.

Provide Interest Coverage Ratio
for Xvivo Perfusion AB.

Provide Altman Z-Score Ratio
for Xvivo Perfusion AB.

Provide Quick Ratio
for Xvivo Perfusion AB.

Provide Current Ratio
for Xvivo Perfusion AB.

Provide Cash Ratio
for Xvivo Perfusion AB.

What is the historical Revenue growth
over the last 5 years for Xvivo Perfusion AB?

What is the historical Net Income growth
over the last 5 years for Xvivo Perfusion AB?

What is the current Free Cash Flow
of Xvivo Perfusion AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for Xvivo Perfusion AB.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Xvivo Perfusion AB

Current Assets 828.1m
Cash & Short-Term Investments 450m
Receivables 188m
Other Current Assets 190.1m
Non-Current Assets 1.5B
Long-Term Investments 42.8m
PP&E 121.7m
Intangibles 1.3B
Current Liabilities 150.8m
Other Current Liabilities 150.8m
Non-Current Liabilities 44.2m
Long-Term Debt 14.7m
Other Non-Current Liabilities 29.5m
Efficiency

Earnings Waterfall
Xvivo Perfusion AB

Revenue
750.6m SEK
Cost of Revenue
-192.1m SEK
Gross Profit
558.5m SEK
Operating Expenses
-501.7m SEK
Operating Income
56.8m SEK
Other Expenses
147.5m SEK
Net Income
204.3m SEK

Free Cash Flow Analysis
Xvivo Perfusion AB

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

XVIVO Profitability Score
Profitability Due Diligence

Xvivo Perfusion AB's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
ROE is Increasing
54/100
Profitability
Score

Xvivo Perfusion AB's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

XVIVO Solvency Score
Solvency Due Diligence

Xvivo Perfusion AB's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Xvivo Perfusion AB's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

XVIVO Price Targets Summary
Xvivo Perfusion AB

Wall Street analysts forecast XVIVO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XVIVO is 544.48 SEK with a low forecast of 484.8 SEK and a high forecast of 613.2 SEK.

Lowest
Price Target
484.8 SEK
7% Upside
Average
Price Target
544.48 SEK
21% Upside
Highest
Price Target
613.2 SEK
36% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for XVIVO?

Click here to dive deeper.

Dividends

Xvivo Perfusion AB
does not pay dividends
Shareholder Yield

Current shareholder yield for XVIVO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

XVIVO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Xvivo Perfusion AB Logo
Xvivo Perfusion AB

Country

Sweden

Industry

Health Care

Market Cap

14.2B SEK

Dividend Yield

0%

Description

Xvivo Perfusion AB is a medical technology company. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 92 full-time employees. The company went IPO on 2012-10-08. The firm operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The firm markets its products in Europe, Asia, Middle East, and North & South America.

Contact

VASTRA GOTALANDS
Goeteborg
Massans Gata 10
+46317882150.0
www.xvivoperfusion.com

IPO

2012-10-08

Employees

92

Officers

Chief Executive Officer
Mr. Christoffer Rosenblad
Chief Financial Officer
Mr. Kristoffer Nordstrom
Chief Operating Officer
Ms. Lena Hagman B.Sc.
Senior Vice President of Commercial EMEA, LATAM, APAC & Global Marketing
Mr. Johan Holmstrom
Global Human Resources Director
Ms. Ylva Vihoj
Senior Advisor
Dr. Magnus Nilsson Ph.D.
Show More
Chief Medical Officer
Mr. Andreas Wallinder M.D., Ph.D.
Senior Vice President of North America
Mr. Mark Reade
Show Less

See Also

Discover More
What is the Intrinsic Value of one XVIVO stock?

The intrinsic value of one XVIVO stock under the Base Case scenario is 251.13 SEK.

Is XVIVO stock undervalued or overvalued?

Compared to the current market price of 451.5 SEK, Xvivo Perfusion AB is Overvalued by 44%.

Back to Top